First treatment for advanced lung cancer with KRAS G12C change
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific genetic marker (KRAS G12C mutation) in your lung cancer.
- You cannot have received any prior treatment for advanced or metastatic lung cancer.
- Your cancer must be advanced or metastatic (stage IIIB/IIIC or IV) and not suitable for surgery or curative radiation.
- You must be between 18 and 75 years old.
- You must be generally healthy (able to care for yourself, not bedridden).
- You must not have certain heart conditions or uncontrolled brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs before surgery for people with a certain type of lung cancer (KRAS G12C). The goal is to see if these drugs can shrink the tumor and improve chances of successful surgery.
This study tests a combination of two drugs: one that targets a specific genetic change in your cancer (KRAS G12C) and one that boosts your immune system to fight the cancer. It's for people who haven't had treatment for advanced or metastatic lung cancer yet.
This study looks at people with advanced or spreading non-small cell lung cancer that has a KRAS G12C mutation, who have already taken the drug IBI-351. It aims to understand how well this drug works in everyday practice and why it might help you.
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new KRAS G12C Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.